Neurocrine Biosciences NBIX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's deferred tax assets and other non-current assets?
- Neurocrine Biosciences (NBIX) reported deferred tax assets and other non-current assets of $73.6M in Q1 2026.
- How has Neurocrine Biosciences's deferred tax assets and other non-current assets changed year-over-year?
- Neurocrine Biosciences's deferred tax assets and other non-current assets increased by 381.0% year-over-year, from $15.3M to $73.6M.
- What is the long-term trend for Neurocrine Biosciences's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets and other non-current assets has grown at a 56.2% compound annual growth rate (CAGR), from $6.4M to $59.5M.